CROI 2016: Top Ten for Clinicians
|
|
- Rosalind Stewart
- 5 years ago
- Views:
Transcription
1 Hynes Convention Center. Boston, MA; US. Feb 22-25, 2016 CROI 2016: Top Ten for Clinicians Josep M Llibre Hospital Universitari Germans Trias i Pujol Fundació Lluita contra la SIDA Badalona, Barcelona jmllibre@flsida.org
2 1. LATTE-2: Dual NRTI/PI-sparing maintenance ART with IM LA CAB + RPV. 2. TAF non-inf to TDF in switch. 3. Doravirine vs EFV naives (+ FTC/TDF): similar efficacy. 4. A single LA CAB dose protects macaques from IV SIV challenge. 5. Dapivirine vaginal rings as PrEP: Significant but limited efficacy. 6. LED/SOF 6 weeks in Acute HCV in HIV+: uncertainty. 7. HIV epidemic through PWID in US could happen again! 8. VRC01 bnab fails to impact viral kinetic rebound. 9. A new 3-in-1 LA adnectin could block any HIV-1 entry. 10. MK-8591: New LA oral and parenteral NRTI translocation inh.
3 LATTE-2 Study Design Primary endpoint: Safety and dose-selection. Induction period CAB 30 mg + + ABC/3TC ABC/3TC for 20 for weeks 20 weeks (N=309) Add RPV Maintenance period a Inclusion criteria CAB 400 mg >18 IM years + RPV old 600 mg IM Naive Q4W to (n=115) antiretroviral therapy CD4+ >200 cells/mm 3 CAB loading dose at Day 1 CAB 600 mg IM + RPV 900 mg IM Exclusion criteria Positive for hepatitis B Q8W (n=115) ALT 5 ULN Creatinine clearance <50 ml/min CAB loading doses at Day 1 and Week 4 Qualification for maintenance CAB 30 mg + ABC/3TC PO QD (n=56) HIV-1 RNA <50 c/ml between Week -4 and Day 1 4 weeks Day 1 Randomization 2:2:1 286/309 (93%) Week 32 Primary analysis Dosing regimen selection Week 48 Analysis Dosing regimen confirmation Week 96 b ABC/3TC, abacavir/lamivudine; ALT, alanine aminotransferase; IM, intramuscular; PO, orally; Q4W, every 4 weeks; Q8W, every 8 weeks; QD, once daily; ULN, upper limit of normal. a Subjects who withdrew after at least 1 IM dose entered the long-term follow-up period. b Subjects can elect to enter LA Extension Phase beyond Week 96. Margolis et al. CROI 2016; Boston, MA. Abstract 31LB. 23rd Conference on Retroviruses and Opportunistic Infections; February 22-25, 2016; Boston, MA
4 LATTE-2 Week 32 Primary Endpoint: HIV-1 RNA <50 c/ml by Snapshot (ITT-ME) Virologic outcomes Treatment differences (95% CI) * * Oral IM Q8W Q4W Both Q8W and Q4W comparable to oral CAB at Week 32 No resistance selection (2VF: 1 Q8W, 1 Oral CAB). ISR common (G1/2) but only 1% of subjects D/C. *Met pre-specified threshold for concluding IM regimen is comparable to oral regimen (Bayesian posterior probability >90% that true IM response rate is no worse than -10% compared with the oral regimen). Margolis et al. CROI 2016; Boston, MA. Abstract 31LB. 23rd Conference on Retroviruses and Opportunistic Infections; February 22-25, 2016; Boston, MA
5 Gallant J. CROI 2016, Boston. #29. Descovy Switch from F/TDF to F/TAF (GS ) Randomized, double-blind, double-dummy, active-controlled study n=333 F/TAF (200/10 or 200/25 mg)* QD F/TDF Placebo QD Virologically Suppressed (< 50 c/ml) F/TDF + Third Agent egfr 50 ml/min 46% Boosted PI 54% Unboosted regimens n=330 Continue Third Agent F/TDF (200/300 mg) QD F/TAF* Placebo QD Continue Third Agent BL Wk 48 Wk 96 Primary Endpoint Secondary * F/TAF Dose: 200/10 mg with boosted PIs 200/25 mg with unboosted third agents HIV-1 RNA <50 c/ml Endpoint 5
6 HIV-1 RNA <50 c/ml, % Gallant J. CROI 2016, Boston. #29. Efficacy at Week 48 (Snapshot) Virologic Outcome Treatment Difference (95% CI) F/TDF F/TAF % 0 +10% AEs D/C: 2% vs 1 % 6
7 HIV-1 RNA <50 c/ml, % Gallant J. CROI 2016, Boston. #29. Virologic Success by Third Agent F/TAF (n=333) F/TDF (n=330) Resistance selection: 1 M184V (F/TAF.) 7
8 Median % change M e d ia n (Q 1, Q 3 ) c h a n g e e G F R * (m L /m in ) Gallant J. CROI 2016, Boston. # Change in Renal Biomarkers at Week F /T A F (n = ) F /T D F (n = ) 8.4 ml/min 2.8 ml/min Protein Urine Protein to Creatinine Ratio Albumin W e e k s p<0.001 (dif: 5.6 ml/min) RBP β2m F/TAF F/TDF All differences between treatments statistically significant (p <0.001) RBP, retinol-binding protein; β2m, β2-microglobulin.
9 Mean % change (95% CI) Gallant J. CROI 2016, Boston. #29. Change in Bone Mineral Density through Week 48 Spine Hip p < p < F/TAF, n F/TDF, n B L Weeks B L Weeks % BMD increase at Week 48 F/TAF 30% 17% p<0.001 F/TDF 14% 9% p=
10 % of Patients (95% CI) 100 DOR vs EFV (+ FTC/TDF). Phase 2 HIV RNA <40 copies/ml (NC=F Approach) CROI 2016 Abstract #470 Boston, MA MK-1439 P007 Gatell JM ,1 72,9 81,5 78,7 77,8 77, ,0 57,5 Week 48 n/n (%) 50 47,2 DOR 84/108 (77.8) ,8 26,9 42,1 EFV 85/108 (78.7) Difference (95% CI): -1.1 (-12.2, 10.0) ,7 12,0 6,5 3,7 DOR 100 mg +TDF/FTC EFV 600 mg +TDF/FTC Treatment Week Good activity against K103N, Y181C, K103N/Y181C, E138K, & K101E, but not Y188L, V106A, M230L Copyright 2016 Merck & Co. Inc. All Rights Reserved. 10
11 Virologic Response by Screening RNA Week 48 (OF Approach*) CROI 2016 Abstract #470 Boston, MA MK-1439 P007 Gatell JM 100,000 c/ml >100,000 c/ml ,6 87,1 89,6 91,9 74,3 83,8 91,4 91, n/n: 58/67 54/ /67 57/ /35 31/37 32/35 34/37 % <40 c/ml % <200 c/ml % <40 c/ml % <200 c/ml DOR 100 mg +TDF/FTC EFV 600 mg +TDF/FTC *Excludes patients who (1)discontinued due to AE, (2) discontinued due to non-treatment related reasons and had last RNA <40 c/ml, or (3) were on-study but missing data in week 48 window. Copyright 2016 Merck & Co. Inc. All Rights Reserved. 11
12 Summary of Week 48 Outcomes (NC=F Approach)* DOR 100 mg (N=108) CROI 2016 Abstract #470 Boston, MA MK-1439 P007 Gatell JM EFV 600 mg (N=108) n (%) n (%) Success (HIV RNA <40 copies/ml) at week (77.8) 85 (78.7) Non-success at week (22.2) 23 (21.3) HIV RNA 40 copies/ml 18 (16.7) 14 (13.0) 40 and <200 copies/ml 8 (7.4) 6 (5.6) 200 copies/ml 3 (2.8) 2 (1.9) discontinued study due to lack of efficacy, or discontinued for other reasons with last HIV RNA 40 copies/ml 7 (6.5) 6 (5.6) No virologic data at week 48 window 6 (5.6) 9 (8.3) discontinued study due to AE or death 3 (2.8) 6 (5.6) discontinued study for other reasons with last HIV RNA <40 copies/ml 3 (2.8) 2 (1.9) on study but missing data in week 48 window 0 (0.0) 1 (0.9) All patients also received TDF/FTC. * Overall success/non-success rates are identical for NC=F and the FDA snapshot approach. Majority of patients in this category (5 of 7 in DOR group; 4 of 6 in EFV group) had last HIV RNA 200 c/ml. No treatment-emergent resistance mutations were detected in the 4 patients (3 DOR, 1 EFV) who had HIV RNA >500 c/ml at the time of virologic failure. DOR Significantly lower rates of: AEs, Neuropsych AEs, Total/LDL Chol G1/2. Copyright 2016 Merck & Co. Inc. All Rights Reserved. 12
13 1. LATTE-2: Dual NRTI/PI-sparing maintenance ART with IM LA CAB + RPV. 2. TAF non-inf to TDF in switch. 3. Doravirine vs EFV naives (+ FTC/TDF): similar efficacy. 4. A single LA CAB dose protects macaques from IV SIV challenge. 5. Dapivirine vaginal rings as PrEP: Significant but limited efficacy. 6. LED/SOF 6 weeks in Acute HCV in HIV+: uncertainty. 7. HIV epidemic through PWID in US could happen again! 8. VRC01 bnab fails to impact viral kinetic rebound. 9. A new 3-in-1 LA adnectin could block any HIV-1 entry. 10. MK-8591: New LA oral and parenteral NRTI translocation inh.
14 Aviremic (%) Two Doses of 50 mg/kg CAB LA Protect 7 of 8 Treated Macaques against SIV IV Challenge CAB LA 100 7/8 80 CAB LA /5 p= Untreated 20 CAB LA Untreated IV Challenge Time (weeks) Infectious dose comparable to a human blood transfusion. No differences in plasma levels in the infected macaque. Andrews C. CROI 2016,Boston, MA. #105.
15 Aviremic (%) Determine if a Single 50 mg/kg CAB LA Dose Provides Sustained CAB Plasma Levels for Protection against IV Challenge CAB LA 1/16 infected (93.3% protection) / /5 p= A Second Dose of CAB LA at Week 4 Is Not Required for Protection against IV Challenge. Results support the evaluation of CAB LA as PrEP in people who inject drugs. 20 CAB LA Untreated IV Challenge Time (weeks) Andrews C. CROI 2016,Boston, MA. #105.
16 Implantable LA ARV Formulations Solid drug core Thin-film polymer membrane Tenofovir alafenamide polycaprolactone biodegradable implant Dissolved drug (saturated) Biological fluid in Dissolved drug out Schlesinger EB. CROI 2016, Boston, MA.#879
17 MTN-020/ASPIRE / The Ring Study Multi-center, randomized, double-blind, placebocontrolled phase III trials of a vaginal matrix ring containing the NNRTI dapivirine. Primary objectives: to determine the effectiveness and safety of dapivirine (25 mg), when inserted once every 4 weeks, in preventing HIV-1 infection among healthy sexually active HIV-1 uninfected women. Median age 26 years, 50% reported not using condoms. Median follow-up: 1.6 (2) years. Pregnancy incidence: 4 (3) %/year. Baeten J. CROI 2016, Boston, MA, #109LB. Nel A. #110 LB.
18 Objective Adherence Assessment Two objective measures, testing dapivirine, were used to assess adherence: Plasma. Measured in quarterly-collected plasma samples: levels >95 pg/ml, indicating at least 8 hours of continuous use, defined adherence. Ring. After the first year of the study, residual drug in returned, used rings was also measured: levels <23.5 mg (= 1.5 mg released, indicating at least some use during the month) defined adherence. Median adherence: 82% (83%). 75% if only residual ring levels. Both studies have 1-2 sites with bad conduct/adherence. Baeten J. CROI 2016, Boston, MA, #109LB. Nel A. #110 LB.
19 ASPIRE / The Ring Study. HIV-1 Protection Primary HIV-1 effectiveness intention-to-treat analysis (15 sites) Dapivirine Placebo # HIV-1 infections 71 (77) 97 (56) HIV-1 incidence, per 100 person-years HIV-1 protection effectiveness 95% CI, p-value 27% (1, 46) p= % (1, 51) P=0.040 No significant protection in women <21 years (HIV incidence: 8.2%/year pbo). Baeten J. CROI 2016, Boston, MA, #109LB. Nel A. #110 LB.
20 The Ring Study. Efficacy by adherence. Note: Adherence based on ring residual level only Nel A. CROI 2016, Boston, MA. #110 LB.
21 1. LATTE-2: Dual NRTI/PI-sparing maintenance ART with IM LA CAB + RPV. 2. TAF non-inf to TDF in switch. 3. Doravirine vs EFV naives (+ FTC/TDF): similar efficacy. 4. A single LA CAB dose protects macaques from IV SIV challenge. 5. Dapivirine vaginal rings as PrEP: Significant but limited efficacy. 6. LED/SOF 6 weeks in Acute HCV in HIV+: uncertainty. 7. HIV epidemic through PWID in US could happen again! 8. VRC01 bnab fails to impact viral kinetic rebound. 9. A new 3-in-1 LA adnectin could block any HIV-1 entry. 10. MK-8591: New LA oral and parenteral NRTI translocation inh.
22 LED/SOF Acute HCV in HIV+. Study Design? Week N=26 LDV/SOF FDC Patients with chronic HIV and acute HCV infection HCV GT 1a (69%) or 4 (31%) ART consistent with LDV/SOF co-administration with HIV <200 copies/ml or not receiving ART with no plans to start Acute HCV infection with detectable HCV RNA (Roche COBAS AmpliPrep/COBAS TaqMan version 2.0, LLOQ=15 IU/mL) for <24 weeks, defined by HCV RNA-positive and negative anti-hcv antibody/hcv RNA test within last 6 months or Elevated ALT/AST >2.5 x ULN in past 6 months with normal LFTs in past year, and other causes excluded 5 sites in Germany and UK SVR12 Rochstroh JK. CROI 2016, Boston, MA. #154LB. 23
23 Patients, % Results: SVR4 and SVR relapsers (2 GT1A, 1 GT4; all IL28B CT) No new NS5A or NS5B RAVs observed at relapse Virologic failures* 4 Virologic failures* 2 Lost to follow-up /26 SVR4 20/26 SVR12 *3 patients relapsed, 1 was reinfected (GT 1a at baseline, 4d in post-treatment). Error bars represent 95% confidence intervals. Rochstroh JK. CROI 2016, Boston, MA. #154LB. 24
24 HCV RNA (log 10 IU/mL) Results: BL HCV RNA and Outcome (SVR) SVR12 SVR4 Relapse Reinfection Rochstroh JK. CROI 2016, Boston, MA. #154LB. 25
25 Austin city pop: Lowest life expectancy. 9% unemployed, 19% poverty, 21% no high school Early 2015: 11 new HIV infections in Scott county (<1/year past decade) 90% coinfected HCV. Network of PWID, oxymorphone (92%) and heroin (23%) N=181 non-hispanic whites (4.6% of adult population) JT Brooks. CROI 2016, Boston, MA. #132. Available at:
26 Time Magazine, 15 June JT Brooks. CROI 2016, Boston, MA. #132. Available at:
27 JT Brooks. CROI 2016, Boston, MA. #132. Available at:
28 IVDU very difficult to monitor HCV epidemic heralds PWID-mediated HIV epidemic. Incidence disproportionally higher in non-urban areas. JT Brooks. CROI 2016, Boston, MA. #132. Available at:
29 JT Brooks. CROI 2016, Boston, MA. #132. Available at:
30 1. LATTE-2: Dual NRTI/PI-sparing maintenance ART with IM LA CAB + RPV. 2. TAF non-inf to TDF in switch. 3. Doravirine vs EFV naives (+ FTC/TDF): similar efficacy. 4. A single LA CAB dose protects macaques from IV SIV challenge. 5. Dapivirine vaginal rings as PrEP: Significant but limited efficacy. 6. LED/SOF 6 weeks in Acute HCV in HIV+: uncertainty. 7. HIV epidemic through PWID in US could happen again! 8. VRC01 bnab fails to impact viral kinetic rebound. 9. A new 3-in-1 LA adnectin could block any HIV-1 entry. 10. MK-8591: New LA oral and parenteral NRTI translocation inh.
31 Anti-PD-L1, Vacc-4x/GM-CSF + Romidepsin, TL7 Agonists, Briostatin,. Mascola JR. CROI 2016, Boston MA. #15.
32 ACTG A5340. VRC01 bnab. Study Design STEP 1: VRC01 administration and Analytical Treatment Interruption Screening Pre-Entry Entry Viral Rebound 1 ary endpoint Study Weeks ATI Weeks HIV <50 for 6 months CD4 > 400 ART Variable duration until HIV VL 1000 copies/ml OR CD4 < 350 HIV viral load/pk Safety (CBC, CD4, CMP) Rectal Biopsy/Leukopheresis VRC01 40 mg/kg ATI 1 week after VRC01 initiation Participants: Chronically infected, on ART with VL<50 copies/ml for > 6 months CD4 count > 400 cells/ml, nadir CD4 > 200 cells/ml INSTI (71%) or PI-based regimen Power: 13 evaluable participants 90% power to detect 40% increase in suppression at week 8 Bar KJ. CROI 2016, Boston, MA. #32LB.
33 Results: Viral rebound HIV-1 RNA (copies/ml) enrollee Weeks post-ati Majority of participants rebounded by week 5 2 participants with delayed rebound at 8, 11 weeks Time to rebound not associated with VRC01 level, age, nadir or entry CD4 ct, time on ART Bar KJ. CROI 2016, Boston, MA. #32LB. A5340
34 Time to HIV-1 RNA 200 c/ml 38% vs. 13% suppression at 4 weeks, p=0.04 8% vs. 3% suppression at 8 weeks, p=0.44 compared to historical controls on non-nnrti regimens undergoing ATI in ACTG studies A5340 Bar KJ. CROI 2016, Boston, MA. #32LB. Li AIDS 2016
35 VRC01 (mcg/ ml) VRC01 (ug/ml) Results: VRC01 levels at rebound VRC01 <3 Doses Washout VRC01 at Rebound ug/ml Weeks post- ATI Weeks 12/13 participants rebounded with plasma VRC01 >50 ug/ml. VRC01 No evidence of viral selection Evidence of resistance development. Bar KJ. CROI 2016, Boston, MA. #32LB. VRC01 at Rebound ATI A5340
36 Mascola JR. CROI 2016, Boston MA. #15.
37 What is an Adnectin? monobodies Adnectins are engineered versions of the 10 th Type III domain of human fibronectin Contain Ig-domain like natural protein binding characteristics A LA (projected human t1/2 40 h) adnectin combining 3 different non-overlapping a-hiv-1 inhibitors would have synergistic advantages Restricted to processes outside the cell (HIV-1 entry) Ability to obtain high potency at low receptor occupancy 3 in 1: αcd4 Adnectin (prevents conformational changes in gp120) + α-gp41 Inhibitors: αn17adnectin (N17 region of HIV) + peptide (more specific that ENF). Krystal M. CROI 2016, Boston, MA. #97.
38 HIV-1 Combinectin: BMS BMS contains 2 a-hiv-1 Adnectins and a peptide fusion inh BMS Ibalizumab CD4 CD4 Binding Coreceptor Binding CCR5 antagonists Maraviroc Virus-Cell Fusion Enfuvirtide Cell Membrane CCR5/CXCR4 NH 2 HSA a-cd4 a-gp41 a-gp41 COOH Krystal M. CROI 2016, Boston, MA. #97.
39 Heightened Resistance Barrier Recombinant viruses were constructed to contain resistance substitutions against one or multiple inhibitors Inhibitor acd4 R an17 R pep R an17 R /pep R acd4 R /an17 R / pep R acd4 Adn 6.8* an17 Adn 0.4 > >799.8 >660 peptide BMS *Fold-Change vs WT virus No significant change in susceptibility with viruses resistant to one of the inhibitors. Only viruses resistant to 2 (an17 + pep) or all 3 inhibitors exhibit high FCs. Suggests resistance barrier to the Combinectin should be higher than mixture of individual components. Krystal M. CROI 2016, Boston, MA. #97.
40 Avg. Change in HIV-1 RNA (log10 c/ml) 1,00 0,50 0,00-0,50-1,00-1,50-2,00-2,50-3,00-3,50-4,00 Efficacy of BMS at Day 36 Vehicle Low dose 1 died Med dose 1/8 Undetectable HAART* 3/6 Undetectable: 2 died Highest dose 6/8 Undetectable Days After Treatment Initiation * RAL + TDF/FTC Dose dependent decrease in viral load Efficacy at highest dose of 197 similar to HAART Study is continuing for an additional 27 days Receptor occupancy and PK consistent over 36 days Krystal M. CROI 2016, Boston, MA. #97.
41 MK-8591, a translocation inh., has an outstanding resistance profile Most potent ARV reported to date (sub-nm in PBMC cell-based assays) Estimated oral t1/2 50 h, plasma (weekly administration) h, PBMCs, phosphorilated metabolite Compound IC 50 (nm) (fold-shift vs WT) WT K65R* M184V** M184I** MK (0.5) 1.6 (8) 0.9 (5) TAF (2.1) 1.6 (0.5) 2.2 (0.7) 3TC (10) >42000 (382) 8900 (81) FTC (8) >42000 (1750) 1400 (58) K65R, the most prevalent mutant associated with TFV, is hypersensitive to MK-8591 MK-8591 exhibits lower fold-changes in potency with M184V/I mutations than 3TC/FTC. Grobler J. CROI 2016, Boston, MA. #98.
42 10 mg oral single dose log Grobler J. CROI 2016, Boston, MA. #98.
43 MK-8591 parenteral formulations release for >180 days Note: < 50% drug released after 180 days >180 day extended release after a single injection in rat Data suggest the potential to provide coverage for up to 1 year Grobler J. CROI 2016, Boston, MA. #98.
23 rd CROI Report Back AETC/Community Consortium Harry W. Lampiris, MD Professor of Clinical Medicine, UCSF Chief, ID Section, Medical Service,
23 rd CROI Report Back AETC/Community Consortium Harry W. Lampiris, MD Professor of Clinical Medicine, UCSF Chief, ID Section, Medical Service, SFVAMC March 23, 2016 Boston, MA, February 22-25, 2016 Disclosures
More informationDidactic Series. CROI New Antiretroviral Therapies. Daniel Lee, MD Clinical Professor of Medicine UCSD Medical Center Owen Clinic July 14, 2016
Didactic Series CROI 2016 - New Antiretroviral Therapies Daniel Lee, MD Clinical Professor of Medicine UCSD Medical Center Owen Clinic July 14, 2016 This project is supported by the Health Resources and
More informationCabotegravir Long-Acting (LA) Injectable Nanosuspension Bill Spreen, for ViiV Healthcare & GSK Development Team. 17 th HIV-HEPPK June 2016
Cabotegravir Long-Acting (LA) Injectable Nanosuspension Bill Spreen, for ViiV Healthcare & GSK Development Team RPV CAB CAB RPV 1 June 2016 Cabotegravir Long-Acting Nanosuspension CAB is an investigational
More informationDRUGS IN PIPELINE. Pr JC YOMBI UCL-AIDS REFERENCE CENTRE BREACH Sept 27, 2015
DRUGS IN PIPELINE Pr JC YOMBI UCL-AIDS REFERENCE CENTRE BREACH Sept 27, 2015 N(t)RTI The Development of TAF TAF Delivers the High Potency of TDF While Minimizing Off- Target Kidney and Bone Side Effects
More informationCabotegravir + Rilpivirine as Long-Acting Maintenance Therapy: LATTE-2 Week 32 Results
Slide 1 Cabotegravir + Rilpivirine as Long-Acting Maintenance Therapy: LATTE-2 Week 32 Results David A. Margolis, 1 Juan Gonzalez-Garcia, 2 Hans-Jürgen Stellbrink, 3 Joe Eron, 4 Yazdan Yazdanpanah, 5 Sandy
More informationTim Horn Deputy Executive Director, HIV & HCV Programs Treatment Action Group NASTAD Prevention and Care Technical Assistance Meeting Washington, DC
Tim Horn Deputy Executive Director, HIV & HCV Programs Treatment Action Group NASTAD Prevention and Care Technical Assistance Meeting Washington, DC July 19, 2017 Pipeline is robust! Several drugs, coformulations,
More informationLong-Acting Antiretrovirals for HIV
Long-Acting Antiretrovirals for HIV R.M. Gulick, MD, MPH Rochelle Belfer Professor in Medicine Chief, Division of Infectious Diseases Weill Cornell Medicine New York City Disclosures None Single Tablet
More information4/14/2016. Breaking News From the 2016 Conference on Retroviruses and Opportunistic Infections
Breaking News From the 2016 Conference on Retroviruses and Opportunistic Infections Jeffrey L. Lennox, MD Professor of Medicine Associate Dean for Clinical Research Emory University School of Medicine
More informationARVs in Development: Where do they fit?
The picture can't be displayed. ARVs in Development: Where do they fit? Daniel R. Kuritzkes, M.D. Division of Infectious Diseases Brigham and Women s Hospital Harvard Medical School Disclosures The speaker
More informationDidactic Series. CROI Update - II. Christian B. Ramers, MD, MPH Family Health Centers of San Diego Ciaccio Memorial Clinic 5/28/15
Didactic Series CROI Update - II Christian B. Ramers, MD, MPH Family Health Centers of San Diego Ciaccio Memorial Clinic 5/28/15 ACCREDITATION STATEMENT: University of California, San Diego School of Medicine
More informationRoy M. Gulick, MD, MPH Rochelle Belfer Professor in Medicine Weill Cornell Medicine New York, New York
Antiretroviral Therapy: Investigational New Drugs and New Strategies Roy M. Gulick, MD, MPH Rochelle Belfer Professor in Medicine Weill Cornell Medicine New York, New York FORMATTED: MM/DD/YY Antiretroviral
More informationCROI 2013: New Drugs for Treatment and PrEP
NORTHWEST AIDS EDUCATION AND TRAINING CENTER CROI 2013: New Drugs for Treatment and PrEP Brian R. Wood, MD Medical Director, NW AETC Project ECHO Assistant Professor of Medicine, University of Washington
More informationACTHIV 2018: A State-of-the-Science Conference for Frontline Health Professionals
ACTHIV 2018: A State-of-the-Science Conference for Frontline Health Professionals ACTHIV 2018: A State-of-the-Science Conference for Frontline Health Professionals Are You Ready? New Drugs Are on the Way!
More informationCROI 2017 Highlights What s New in Antiretrovirals (Part 2)
Mountain West AIDS Education and Training Center CROI 2017 Highlights What s New in Antiretrovirals (Part 2) Ann Collier, MD This presentation is intended for educational use only, and does not in any
More informationLong Acting ART for Treatment and PrEP
Long Acting ART for Treatment and PrEP Anton Pozniak MD FRCP Consultant Physician Disclosures I have received honoraria, travel sponsorship and research grants from: Gilead Sciences Janssen MSD ViiV Healthcare
More informationRESEARCH B/F/TAF in Treatment-Naïve HIV-1 and HIV-1 RNA Suppressed Switch Patients
RESEARCH B/F/TAF in Treatment-Naïve HIV-1 and HIV-1 RNA Suppressed Switch Patients Kirsten White Gilead Sciences, Inc., Foster City, CA Background Bictegravir (BIC; B) is a novel, unboosted integrase strand
More informationOral Versus Injectable Delivery, Impact on Adherence/Tolerability
Oral Versus Injectable Delivery, Impact on Adherence/Tolerability 2 nd European HIV Forum Ian McGowan MD DPhil FRCP University of Pittsburgh, PA, USA Glasgow, 22 nd October, 2016 Overview Why do we need
More informationBHIVA Best of CROI Feedback Meetings
BHIVA Best of CROI Feedback Meetings London Birmingham Haydock Newcastle Cardiff Wakefield Edinburgh BHIVA Best of CROI Feedback Meetings 2016 New drugs Dr David Asboe Chelsea and Westminster Hospital,
More informationAntiretroviral Treatment: What's in the Pipeline
Antiretroviral Treatment: What's in the Pipeline Joseph P. McGowan, MD, FACP, FIDSA Professor of Medicine Hofstra North Shore-LIJ School of Medicine October 14, 2015 Which describes best how HIV Maturation
More informationAntiretroviral Therapy in 2016
Antiretroviral Therapy in 2016 Joel Gallant, MD, MPH Southwest CARE Center Santa Fe, NM University of New Mexico School of Medicine Johns Hopkins University School of Medicine Disclosures Consulting, Advisory
More informationInvestigational Approaches to Antiretroviral Therapy: New Strategies and Novel Agents
Investigational Approaches to Antiretroviral Therapy: New Strategies and Novel Agents Joseph J. Eron MD Professor of Medicine University of North Carolina Chapel Hill, North Carolina Learning Objectives
More informationDisclosures (last 12 months)
HIV Research What s in the Pipeline? Samir K. Gupta, MD, MS Division of Infectious Diseases Indiana University School of Medicine Disclosures (last 12 months) Independent research grant funding by NIH/NHLBI,
More informationTaking a shot at HIV with longacting injectable ARVs for treatment and prevention
Taking a shot at HIV with longacting injectable ARVs for treatment and prevention Martin Markowitz M.D. Clinical Director and Staff Investigator Aaron Diamond AIDS Research Center Aaron Diamond Professor
More informationAre the current doses of ARV correct. Richard Elion MD Associate Adjunct Clinical Professor of Medicine Johns Hopkins School of Medicine
Are the current doses of ARV correct Richard Elion MD Associate Adjunct Clinical Professor of Medicine Johns Hopkins School of Medicine Can we lower doses of HIV meds safely? Consensus Panel in Alexandria
More informationThe injectables: a new silver bullet?
The injectables: a new silver bullet? Geneva October 6 Francois Venter Wits Reproductive Health and HIV Institute Thanks Clinical Care Options, Helen Rees, Joe Eron, Wits RHI sex worker team Disclosures
More informationActualización y Futuro en VIH
Actualización y Futuro en VIH Dr. Santiago Moreno Servicio de Enfermedades Infecciosas Hospital U. Ramón y Cajal. Universidad de Alcalá. IRYCIS. Madrid Agenda Control of the HIV-epidemic Coinfections Antiretroviral
More informationWHEN TO START? CROI 2015: Focus on ART
CROI 215: Focus on ART FORMATTED: 4-1-15 Washington, DC: May 13, 215 Roy M. Gulick, MD, MPH Gladys and Roland Harriman Professor of Medicine Chief, Division of Infectious Diseases Weill Cornell Medical
More informationCase 1 continued. Case 1 (cont) 12/8/16. MMAH Debate Panel Thursday, December 8, Case 1
MMAH Debate Panel Thursday, December 8, 2016 Case 1 HPI 55 yo man with newly diagnosed HIV initiates care in your clinic. His CD4+ cell count is 600, with HIV VL=90,000 copies/ml. He is asymptomatic at
More informationUpdate on HIV Drug Resistance. Daniel R. Kuritzkes, MD Division of Infectious Diseases Brigham and Women s Hospital Harvard Medical School
Update on HIV Drug Resistance Daniel R. Kuritzkes, MD Division of Infectious Diseases Brigham and Women s Hospital Harvard Medical School Learning Objectives Upon completion of this presentation, learners
More informationManagement of patients with antiretroviral treatment failure: guidelines comparison
The editorial staff Management of patients with antiretroviral treatment failure: guidelines comparison A change of therapy should be considered for patients if they experience sustained rebound in viral
More informationSINGLE. Efficacy and safety of dolutegravir (DTG) in treatment-naïve subjects
SINGLE Efficacy and safety of dolutegravir (DTG) in treatment-naïve subjects SE/HIV/0023/14 January 2014 PHASE III DTG TRIALS IN TREATMENT-NAÏVE ADULT SUBJECTS WITH HIV SINGLE 1 N=833 Phase III non-inferiority,
More informationFuture Perspectives for Delivery of Antiretroviral Drugs
Future Perspectives for Delivery of Antiretroviral Drugs David Back University of Liverpool UK David Back University of Liverpool Disclosures Honoraria received for advisory boards and lectures from AbbVie,
More informationManagement of Treatment-Experienced Patients: New Agents and Rescue Strategies. Joel E. Gallant, MD, MPH Johns Hopkins University School of Medicine
Management of Treatment-Experienced Patients: New Agents and Rescue Strategies Joel E. Gallant, MD, MPH Johns Hopkins University School of Medicine When to Modify Therapy! Studies to date show better responses
More informationReduced drug regimens. Josep M Llibre Infectious Diseases & Fight AIDS Fndn Univ Hosp Germans Trias i Pujol Badalona, Barcelona
Reduced drug regimens Josep M Llibre Infectious Diseases & Fight AIDS Fndn Univ Hosp Germans Trias i Pujol Badalona, Barcelona jmllibre@flsida.org 9th IAS Conference on HIV Science (IAS 2017) 23 26 July
More informationVirological suppression and PIs. Diego Ripamonti Malattie Infettive - Bergamo
Virological suppression and PIs Diego Ripamonti Malattie Infettive - Bergamo Ritonavir-boosted PIs Boosted PIs: 3 drugs in one The intrinsic antiretroviral activity Viral suppression and high baseline
More informationART Treatment. ART Treatment
Naïve Experienced Strategies ARV in pregnancy ART Treatment Naïve studies: ART Treatment Abstract 37 Atazanavir/r vs Lopinavir/r: Castle study Abstract 774 Kivexa vs Truvada: HEAT study Abstract 775 Lopinavir/r
More informationHIV 101. Applications of Antiretroviral Therapy
HIV 101. Applications of Antiretroviral Therapy Michael S. Saag, MD Professor of Medicine Associate Dean for Global Health Jim Straley Chair in AIDS Research University of Alabama at Birmingham Birmingham,
More informationREASONS FOR DISCONTINUATION OF DUAL THERAPY WITH DOLUTEGRAVIR AND RILPIVIRINE
REASONS FOR DISCONTINUATION OF DUAL THERAPY WITH DOLUTEGRAVIR AND RILPIVIRINE R. Montejano, N. Stella-Ascariz, S. Garcia-Bujalance, JI. Bernardino, V. Hontañon, R. Mican, Montes M, E. Valencia, J. González,
More informationHIV IS NOT OVER. Update From the Conference on Retroviruses and Opportunistic Infections (CROI) Learning Objectives
Update From the Conference on Retroviruses and Opportunistic Infections (CROI) Davey M. Smith, MD, MAS Professor of Medicine University of California San Diego San Diego, California Learning Objectives
More informationNuevos fármacos an/retrovirales
Nuevos fármacos an/retrovirales Pere Domingo Malal/es Infeccioses Hospitals Universitaris Arnau de Vilanova & Santa María IRB Lleida Universitat de Lleida pdomingo@gss.scs.es La escasez persiste... Combinec/n:
More informationSwitching strategies and ARV treatment costs
February 2014 Switching strategies and ARV treatment costs Josep M Llibre/Bonaventura Clotet Fundació Lluita contra la SIDA Hosp Univ Germans Trias i Pujol Badalona Rationale. Spain is under a huge economic
More informationInvestigational Approaches to Antiretroviral Therapy
Investigational Approaches to Antiretroviral Therapy Rajesh T. Gandhi, MD Massachusetts General Hospital Professor of Medicine Harvard Medical School Boston, Massachusetts Learning Objectives After attending
More informationDavid Cluck, PharmD, BCPS, AAHIVP Associate Professor of Pharmacy Practice Office 326 Phone
David Cluck, PharmD, BCPS, AAHIVP Associate Professor of Pharmacy Practice Office 326 Phone 423-439-6245 Email cluckd@etsu.edu Recall newly approved antiretrovirals and their respective place in therapy
More informationAntiretroviral Treatment Strategies: Clinical Case Presentation
Antiretroviral Treatment Strategies: Clinical Case Presentation Department of Internal Medicine, Far Eastern Memorial Hospital, New Taipei City, Taiwan Chia-Jui, Yang M.D Disclosure No conflicts of interests.
More informationSwitching ARV Regimens: Managing Toxicity and Improving Tolerability; Switches & Class-Sparing Approaches
Switching ARV Regimens: Managing Toxicity and Improving Tolerability; Switches & Class-Sparing Approaches Harry W. Lampiris, MD Chief, Infectious Disease Section, San Francisco VA Medical Center Professor
More informationHIGH VIRAL LOAD AND TREATMENT RESPONSE
16 th Annual Resistance and Antiviral Dr Bonaventura Clotet Hospital Germans Trias i Pujol, Barcelona, Spain Thursday 20 September 2012, Wellcome Collection Conference Centre, London HIGH VIRAL LOAD AND
More informationICVH 2016 Oral Presentation: 28
Ledipasvir/Sofosbuvir Is Safe and Effective for the Treatment of Patients with Genotype 1 Chronic HCV Infection in Both HCV Mono- and HIV/HCV Coinfected Patients A Luetkemeyer 1, C Cooper 2, P Kwo 3, K
More informationManagement of ART Failure. EACS Advanced HIV Course 2015 Dr Nicky Mackie
Management of ART Failure EACS Advanced HIV Course 2015 Dr Nicky Mackie Outline Defining treatment success Defining treatment failure Reasons for ART failure Management of ART failure Choice of second
More informationThe pipeline: Long-acting agents and new drugs. Charles Flexner, MD Johns Hopkins University
The pipeline: Long-acting agents and new drugs Charles Flexner, MD Johns Hopkins University Do we still need an ARV pipeline? How close are we to having a universal antiretroviral regimen? A universal
More informationCROI 2017 Review: Novel ART Strategies
Mountain West AIDS Education and Training Center CROI 2017 Review: Novel ART Strategies Brian R. Wood, MD Assistant Professor of Medicine Medical Director, Mountain West AETC ECHO Telehealth March 2, 2017
More informationHow to best manage HIV patient?
How to best manage HIV patient? 1 2 Treatment Treatment Failure success HIV therapy = a long life therapy Why do we want to change a suppressive ART? Side effect Comorbidities Reduce drug burden How to
More informationTreatment strategies for the developing world
David A Cooper National Centre in HIV Epidemiology and Clinical Research The University of New South Wales Sydney, Australia First line standard of care First line in the developing world First line failure
More information2 nd Line Treatment and Resistance. Dr Rohit Talwani & Dr Dave Riedel 12 th June 2012
2 nd Line Treatment and Resistance Dr Rohit Talwani & Dr Dave Riedel 12 th June 2012 Overview Basics of Resistance Treatment failure Strategies to manage treatment failure Mutation Definition: A change
More informationNew options for new and old patients. Antonella Castagna
New options for new and old patients Antonella Castagna Disclosures I have received funding for Advisory Boards, Speaker Panels and for preparation of educational materials from the following: Gilead Sciences
More informationHIV Update Allegra CPD Day Program Port Elizabeth Dr L E Nojoko
HIV Update 2014 Allegra CPD Day Program Port Elizabeth 12-02-2014 Dr L E Nojoko Global estimates for adults and children 2011 People living with HIV 34.0 million [31.4 million 35.9 million] New HIV infections
More informationAbstract PS8/2. Double-blind treatment phase D/C/F/TAF. + matching D/C + F/TDF placebo D/C/F/TAF. D/C + F/TDF + matching D/C/F/TAF placebo
WEEK 8 RESULTS OF AMBER: A PHASE 3, RANDOMISED, DOUBLE-BLIND TRIAL IN ANTIRETROVIRAL TREATMENT (ART)-NAÏVE HIV--INFECTED ADULTS TO EVALUATE THE EFFICACY AND SAFETY OF THE ONCE-DAILY, SINGLE-TABLET REGIMEN
More informationWhat is the Virologic Support for Two-Drug Regimens?
What is the Virologic Support for Two-Drug Regimens? Daniel R. Kuritzkes, M.D. Division of Infectious Diseases Brigham and Women s Hospital Harvard Medical School Disclosures The speaker has received consulting
More informationInvestigational Approaches to Antiretroviral Therapy
Investigational Approaches to Antiretroviral Therapy Rajesh T. Gandhi, MD Massachusetts General Hospital Professor of Medicine Harvard Medical School Boston, Massachusetts Learning Objectives After attending
More informationThe Integrase Inhibitor Drug Class: A Comparative Clinical Review
The Integrase Inhibitor Drug Class: A Comparative Clinical Review Ian Frank Professor of Medicine University of Pennsylvania Philadelphia, PA USA franki@pennmedicine.upenn.edu Disclosure Gilead, ViiV/GlaxoSmithKline:
More informationDr Carole Wallis, PhD Medical Director, BARC-SA Head of the Specialty Molecular Division, Lancet Laboratories, South Africa
Dr Carole Wallis, PhD Medical Director, BARC-SA Head of the Specialty Molecular Division, Lancet Laboratories, South Africa Transmitted drug resistance Resistance patterns in first-line failures in adults
More informationTreating HIV: When the Guidelines Don t Fit. Joel Gallant, MD, MPH. Southwest CARE Center Santa Fe, New Mexico
Treating HIV: When the Guidelines Don t Fit Joel Gallant, MD, MPH Southwest CARE Center Santa Fe, New Mexico Johns Hopkins University School of Medicine University of New Mexico School of Medicine Disclosures
More informationv Dr Anton Pozniak Chelsea and Westminster Hospital, London Injectable ARVs a S.W.O.T Analysis
18 th Annual Resistance and Antiviral Therapy Meeting v Dr Anton Pozniak Chelsea and Westminster Hospital, London Thursday 18 September 2014, Royal College of Physicians, London Injectable ARVs a S.W.O.T
More informationEfficacy and Safety of Doravirine 100mg QD vs Efavirenz 600mg QD with TDF/FTC in ART-Naive HIV-Infected Patients: Week 24 Results
Efficacy and Safety of Doravirine 1mg QD vs Efavirenz 6mg QD with TDF/FTC in ART-Naive HIV-Infected Patients: Week 24 Results Jose M. Gatell, Francois Raffi, Andreas Plettenberg, Don Smith, Joaquin Portilla,
More informationHIV life cycle revisited: What s new in basic science? Theresa Rossouw
HIV life cycle revisited: What s new in basic science? Theresa Rossouw Outline of the Presentation Lifecycle overview New drugs & therapies Cell entry Co-receptor binding Attachment Keeping it Simple
More informationDolutegravir Attributes
Dolutegravir (; S/GSK1349572) in Combination Therapy Exhibits Rapid and Sustained Antiviral Response in Antiretroviral Naïve Adults: 96 Week Results from SPRING 1 (ING112276) Hans Juergen Stellbrink, 1
More informationHIV Treatment: New and Veteran Drugs Classes
HIV Treatment: New and Veteran Drugs Classes Jonathan M Schapiro, MD National Hemophilia Center Stanford University School of Medicine Rome, March 2013 Overview Many excellent antiretroviral agents are
More informationMDR HIV and Total Therapeutic Failure. Douglas G. Fish, MD Albany Medical College Albany, New York Cali, Colombia March 30, 2007
MDR HIV and Total Therapeutic Failure Douglas G. Fish, MD Albany Medical College Albany, New York Cali, Colombia March 30, 2007 Objectives Case study Definitions Fitness Pathogenesis of resistant virus
More informationSimplifying HIV Treatment Now and in the Future
Simplifying HIV Treatment Now and in the Future David M. Hachey, Pharm.D., AAHIVP Professor Idaho State University Department of Family Medicine Nothing Disclosure 1 Objectives List current first line
More informationReduced Drug Regimens
Dr. Jose R Arribas @jrarribas Financial disclosures JOSE R ARRIBAS Research Support: Speaker s Bureau: Viiv, Janssen, Abbvie, BMS, Gilead, MSD Board Member/Advisory Panel: Merck, Gilead Stock/Shareholder:
More informationClinical support for reduced drug regimens. David A Cooper The University of New South Wales Sydney, Australia
Clinical support for reduced drug regimens David A Cooper The University of New South Wales Sydney, Australia Clinical support for reduced drug regimens First line optimisation Virological failure New
More informationSwitching antiretroviral therapy to safer strategies based on integrase inhibitors. Pedro Cahn
Switching antiretroviral therapy to safer strategies based on integrase inhibitors Pedro Cahn Disclosures Research Grants: Abbvie-Merck-Richmond-ViiV Advisory boards: Merck-Sandoz-ViiV Switching in Virologically
More informationThe next generation of ART regimens
The next generation of ART regimens By Gary Maartens Presented by Dirk Hagemeister Division of Clinical Pharmacology UNIVERSITY OF CAPE TOWN IYUNIVESITHI YASEKAPA UNIVERSITEIT VAN KAAPSTAD Current state
More informationTwo Drug Regimens Pros and Cons. Jürgen Rockstroh Department of Medicine I University Hospital Bonn, Bonn, Germany
Two Drug Regimens Pros and Cons Jürgen Rockstroh Department of Medicine I University Hospital Bonn, Bonn, Germany HIV Clinical Forum, Moscow, Russia, Friday 23 rd November 2018 Conflict of Interest: JKR
More informationSTRIBILD (aka. The Quad Pill)
NORTHWEST AIDS EDUCATION AND TRAINING CENTER STRIBILD (aka. The Quad Pill) Brian R. Wood, MD Medical Director, NW AETC ECHO Assistant Professor of Medicine, University of Washington Presentation prepared
More informationThe Science behind Preexposure Prophylaxis (PrEP) Yunus Moosa Department of Infectious Diseases UKZN
The Science behind Preexposure Prophylaxis (PrEP) Yunus Moosa Department of Infectious Diseases UKZN 1 Ongoing HIV transmission despite expanding access to ART SA 18 16 14 12 10 8 6 4 2 0 Treatment exposure
More informationDNA Genotyping in HIV Infection
Frontier AIDS Education and Training Center DNA Genotyping in HIV Infection Steven C. Johnson M.D. Director, University of Colorado HIV/AIDS Clinical Program; Professor of Medicine, Division of Infectious
More informationCROI 2016 Update NEAETC, March 21, Sigal Yawetz, MD Brigham and Women s Hospital Harvard Medical School
CROI 2016 Update NEAETC, March 21, 2016 Sigal Yawetz, MD Brigham and Women s Hospital Harvard Medical School CROI 2016 Update NEAETC, March 21, 2016 UNITED STATES EPIDEMIOLOGY Estimating the lifetime risk
More informationCROI 2018 Report Back
CROI 2018 Report Back Monika Roy, MD MAS Assistant Professor Division of HIV, Infectious Diseases, and Global Medicine bayareaaetc.org 1 Disclosures and Conflicts of Interest Nothing to report bayareaaetc.org
More informationBon Usage des Antirétroviraux dans l Infection par le VIH
Bon Usage des Antirétroviraux dans l Infection par le VIH Pr. Jean-Michel Molina CHU St Louis, Assistance Publique Hôpitaux de Paris, INSERM U941 et Université Paris 7 Diderot, France 1 Liens d Intérêt
More informationProfessor Jeffery Lennox
BHIVA AUTUMN CONFERENCE 2014 Including CHIVA Parallel Sessions Professor Jeffery Lennox Emory University School of Medicine Atlanta, Georgia, USA 9-10 October 2014, Queen Elizabeth II Conference Centre,
More informationUpdate From the 2018 Conference on Retroviruses and Opportunistic Infections (CROI)
Update From the 2018 Conference on Retroviruses and Opportunistic Infections (CROI) W. David Hardy, MD Senior Director of Evidence-based Practices Whitman-Walker Health Clinical Professor of Medicine George
More informationMucosal Assays in Oral and Long Acting (LA) Antiretroviral PrEP Trials. Ian McGowan MD PhD FRCP University of Pittsburgh Pittsburgh, PA USA
Mucosal Assays in Oral and Long Acting (LA) Antiretroviral PrEP Trials Ian McGowan MD PhD FRCP University of Pittsburgh Pittsburgh, PA USA Overview A brief history of oral/la PrEP research Integration
More informationCROI 2018 Update. Christian B. Ramers, MD, MPH, AAHIVS. Assistant Medical Director - Research/Special Populations Family Health Centers of San Diego
CROI 2018 Update Christian B. Ramers, MD, MPH, AAHIVS Assistant Medical Director - Research/Special Populations Family Health Centers of San Diego Assistant Clinical Professor UC San Diego School of Medicine
More informationDevelopment of a protease inhibitor-based single-tablet complete HIV-1 regimen of darunavir/cobicistat/emtricitabine/tenofovir
Development of a protease inhibitor-based single-tablet complete HIV-1 regimen of darunavir/cobicistat/emtricitabine/tenofovir alafenamide () Bryan Baugh 1, Erika Van Landuyt 2, Simon Vanveggel 2, Herta
More informationCases: Treatment of Hepatitis C in HIV/HCV Coinfection
Cases: Treatment of Hepatitis C in HIV/HCV Coinfection David L. Wyles, MD Professor of Medicine University of Colorado Chief, Division of Infectious Disease Denver Health Learning Objectives After attending
More informationWhat s in the Biomedical Prevention Pipeline
What s in the Biomedical Prevention Pipeline HIV Endgame: Closing Gaps in the Care Cascade Toronto, 24 th October 2016 Ian McGowan MD DPhil FRCP University of Pittsburgh Pittsburgh, PA, USA Presenter Disclosure
More informationSecond-Line Therapy NORTHWEST AIDS EDUCATION AND TRAINING CENTER
NORTHWEST AIDS EDUCATION AND TRAINING CENTER Second-Line Therapy David Spach, MD Clinical Director, Northwest AETC Professor of Medicine, Division of Infectious Diseases University of Washington Presentation
More informationDr Marta Boffito 15/10/ th Annual Resistance and Antiviral Therapy Meeting. Chelsea and Westminster Hospital, London
18 th Annual Resistance and Antiviral Therapy Meeting Dr Marta Boffito Chelsea and Westminster Hospital, London Thursday 18 September 2014, Royal College of Physicians, London 1 virological response (SVR)
More informationThis graph displays the natural history of the HIV disease. During acute infection there is high levels of HIV RNA in plasma, and CD4 s counts
1 2 This graph displays the natural history of the HIV disease. During acute infection there is high levels of HIV RNA in plasma, and CD4 s counts decreased. This period of acute infection or serocnversion
More informationDr Marta Boffito Chelsea and Westminster Hospital, London
Dr Marta Boffito Chelsea and Westminster Hospital, London Speaker Name Statement Dr Marta Boffito has received travel and research grants from and has been an advisor for Janssen, Roche, Pfizer, ViiV,
More information11/7/2016. Jeanne M. Marrazzo, MD, MPH Professor of Medicine University of Alabama at Birmingham Birmingham, Alabama
HIV Preexposure Prophylaxis: Pills, Rings, Injectables, and Gels Oh My! Jeanne M. Marrazzo, MD, MPH Professor of Medicine University of Alabama at Birmingham Birmingham, Alabama FORMATTED: 10/17/16 Financial
More informationDidactic Series. CROI 2014 Update. March 27, 2014
Didactic Series CROI 2014 Update Christian Ramers, MD, MPH Family Health Centers of San Diego Ciaccio Memorial Clinic Jacqueline Peterson Tulsky, MD UCSF Positive Health Program at SFGH Medical Director,
More informationIntegrase Inhibitors in the Treatment HIV-Infection. Andrew Zolopa, MD Stanford University
Integrase Inhibitors in the Treatment HIV-Infection Andrew Zolopa, MD Stanford University 1 IAS-USA 212 Guidelines Updated Recommendations When to start ART is now recommended for all patients, regardless
More informationUpdate on Biomedical Prevention. Thomas C. Quinn, MD, MSc
Update on Biomedical Prevention Thomas C. Quinn, MD, MSc Associate Director of International Research National Institute of Allergy and Infectious Diseases Director, Johns Hopkins Center for Global Health
More informationID Week 2016: HIV Update
Mountain West AIDS Education and Training Center ID Week 2016: HIV Update Robert Harrington, M.D. This presentation is intended for educational use only, and does not in any way constitute medical consultation
More informationResistance Workshop. 3rd European HIV Drug
3rd European HIV Drug Resistance Workshop March 30-April 1 st, 2005 Christine Hughes, PharmD Clinical Associate Professor Faculty of Pharmacy & Pharmaceutical Sciences University of Alberta Tenofovir resistance
More informationHIV replication and selection of resistance: basic principles
HIV replication and selection of resistance: basic principles 26th International HIV Drug Resistance and Treatment Strategies Workshop Douglas Richman 6 November 2017 CLINICAL DATA DURING SIXTEEN WEEKS
More informationARV Update: 2016 and Beyond Antonio E. Urbina, MD Associate Professor of Medicine Icahn School of Medicine Mount Sinai Hospital
ARV Update: 2016 and Beyond Antonio E. Urbina, MD Associate Professor of Medicine Icahn School of Medicine Mount Sinai Hospital Disclosures Scientific Advisory Panels: Gilead, Thera technologies, Merck,
More informationNew Delivery Systems and Long Acting Antiretroviral Drugs
New Delivery Systems and Long Acting Antiretroviral Drugs David Back University of Liverpool UK David Back University of Liverpool Prague October 2018 Disclosures Honoraria received for advisory boards
More informationGuidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents
Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents Visit the AIDSinfo website to access the most up-to-date guideline. Register for e-mail notification of guideline
More information